Genmab — Juni 2020

[Bulder]

Median prior lines = 3 for both

[E_L]

yes. even though a bit more toxic?

[E_L]

and it seems higher dose for glofitamab do not make a lot of difference?

[E_L]

hopefully for epco it does. only 4 patients in figure 4 at the 48mg so far and i assume they have been on that for the shortest time (compared to others)

[Solsen]

Yes thats the question. But normally higher dose more effective and more toxic. But I couldnt se that clearely in recent data. Small group and hard to se.

[E_L]

well if it is true that they will start 10 epco trials we will have a lot of data to look forward to lol

[E_L]

I wonder if we are going to repeat the whole Dara experience again...

[StockBull]

nyt TA signal https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/84651_nyt_genmab_signal.JPG

[Bulder]

I suppose the expansion part will be ready for ASH

[Bulder]

If not CMD 30/11

[gentogen]

Med en rising wedge går jeg ud fra, at vi snart kan supplere billigt igen - eller hvordan er det nu med det

[Vitus]

Markedet og Genmab faldt tilbage den sidste halve time...

[Legolas23]

Sikker

[nohope]

Lille tab i fri pf, større gevinst i pension pf. Ærgerligt det faldt tilbage mod luk.

[Solsen]

Heller ikke vin i aften nohope. Du bliver rig af alt det vin du sparer

[Helge_LarsenPI-redaktør]

Genmabs poster discussions on epcoritamab (DuoBody-CD3xCD20), HexaBody-CD38, and DuoHexaBody-CD37 are now
available to view on demand. https://ehaweb.org/congress/eha25/virtual/

[Solsen]

Gode data fra vores venner Abbvie i psoriasis https://finance.yahoo.com/news/abbvie-presents-breaking-data-showing-190200489.html

[Jazzz]

Nogen der forstår baggrunden for at HSBC år efter år sætter Genmab så lavt.. mærkeligt og helt ude af trit...

[bibob]

Dr Hari on the role of MRD in MM. https://www.onclive.com/view/dr-hari-on-the-role-of-mrd-in-multiple-myeloma?eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

[E_L]

Adding Daratumumab to CyBorD Improves Outcomes for AL Amyloidosis https://www.onclive.com/view/adding-daratumumab-to-cybord-improves-outcomes-for-al-amyloidosis